Author  
Place of duty  
Title   악성 종양 환자에서 재조합 감마 인터페론 ( LBD - 001 ) 의 제 2 상 임상실험 ( Phase 2 Trial of Recombinant Interferon - Gamma ( LBD - 001 ) in Patients with Malignancies )
Publicationinfo   1992 Jan; 024(04): 549-562.
Key_word   Interferon-gamma, Immunotherapy, Renal cell carcinoma, Malignant melanoma, Chronic myelogenous leukemia
Full-Text  
Abstract   Metastatic rena1 cell carcinoma, malignant melanoma and chronic myelogenous leukemia are resistant to the conventional cytotoxic anticancer chemotherpay. Therefore there have been many therapeutic trials of immunotherapy for these diseases. Alpha-interferon was widely used and resulted in the response rate of 10 to 20%. Gamma-interferon has been expected to have more potent antitumor effect theoretically and better efficacy clinically. We conducted a phase II study of recombinant interferon-gamma(LBD-OOI, produced by Lucky, Co.) in patients with metastatic renal cell carcinoma or malignant melanoma or Phila- delphia-chromosome positive chronic myelogenous leukemia from Feb. 1989 to Dec. 1991. The schedule was the intramuscular administration of recombinant interferon-gamma 10x 10(6)u/m(2) /day six consecutive days a week for two weeks followed by two weeks of rest and was repeated every four weeks. In renal cell carcinoma, 4 in 26 patients had partial remission(response rate 15.4%) and their remission duration was 20, 23, 56, 78+ weeks respectively. Time to proaression was 4 to 90+ weeks(median 17 weeks). In malignant melanoma, one out of 20 patients had partial remission and its remission duration was 28 weeks. Time to progression was 2 to 57 weeks(median 6 weeks). In chronic myelogenous leukemia, 2 out of 14 patients(l4.2%) had hematological partial remission and their remission duration was 6 and 124' weeks. Cytogenetically, there were l(7.1%) camplete remission, 3(21.4%) partial remission and 3(21.4%) minimal response. As side effects, fever occured freque#ntly but managesble with antipyretics and hepatotoxicity and neu- tropenia were tolerable. We concluded that recombinant interferon-gamma
저 자   서창인(Chang In Suh),강원기(Won Ki Kang),김홍태(Heung Tae Kim),이재훈(Jae Hoon Lee),허대석(Dae Seog Heo),방영주(yung Jue Bang),박선양(Seonyang Park),김병국(Byoung Kook Kim),김노경(Noe Kyeong Kim),박영석(Young Suk Park),박근칠(Keun Chil Park),김성록(Sung Rok Kim),이상재(Sang Jae Lee)